Baxter Healthcare's Dexmedetomidine Hydrochloride ANDA208103 Receives AP Status
Baxter Healthcare Corporation's application for Dexmedetomidine Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.
Therapeutic Area
Therapeutic area intelligence for Sedative with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.